RT Journal
A1 Kuehn BM
T1 EFalizumab withdrawn
JF JAMA
JO JAMA
YR 2009
FD May 27
VO 301
IS 20
SP 2085
OP 2085
DO 10.1001/jama.2009.712
UL http://dx.doi.org/10.1001/jama.2009.712
AB 
The phased withdrawal will be completed by June 8, 2009. In the meantime, the agency advises against prescribing the drug for new patients and urges physicians to immediately begin transitioning patients to other therapies.